oneplacenewsSource: NPR Health
Summary
A key FDA committee has unanimously recommended Moderna’s new mRNA influenza vaccine for adults aged 50 and older. This marks the first vaccine endorsement by the committee since 2023.
Why It Matters
The recommendation of Moderna’s mRNA influenza vaccine is significant as it provides a new option for protecting older adults against the flu, a group that is particularly vulnerable to severe illness. As the flu season approaches, this innovative vaccine could enhance public health outcomes and reduce hospitalizations among seniors.
